Dr. O'Brien Discusses Ibrutinib and Idelalisib in CLL

Susan M. O'Brien, MD, associate director, Clinical Science Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, Chao Family Comprehensive Cancer Center, University of California at Irvine, discusses the use of ibrutinib and idealisib in chronic lymphocytic leukemia (CLL).

One of the advantages to treating patients with either ibrutinib or idelalisib is that neither agent is myelosuppressive. Therefore, chemotherapy-based regimens, which are myelosuppressive, are a difficult choice to administer to patients.

Ibrutinib and idelalisib have also demonstrated improvement in cytopenia. O’Brien says that, for patients with baseline cytopenia, practitioners should not reduce treatment dosage in order to have a rapid improvement. Durable responses have been seen with the use of both agents in the relapsed/refractory setting, she adds, though median progression-free survival (28 months) has only been reached in patients with 17p deletion.

<<<

View more from the 13th International Conference on Malignant Lymphoma